Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Shinichi Miyamori"'
3
Relationship between the Effectiveness and Dose of Micafungin in the Treatment of Candidemia
Autor: Takafumi Sugawara, Shunji Matsumoto, Nobue Uetake, Shinichi Miyamori, Ryouichi Okamoto, Noritaka Murakami, Kouichi Hiraki
Publikováno v: YAKUGAKU ZASSHI. 134:433-438
The Guidelines for Management of Deep-seated Mycoses 2007 recommend the use of micafungin as a first-line agent for the treatment of candidemia. On the package insert, the recommended dose of micafungin is 50 mg/d. However, the Guidelines recommend a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64efd7eefdef10d7efc60b0a8888e24a
https://doi.org/10.1248/yakushi.13-00238
Zobrazit plný text záznamu
4
Analysis of Risk Factors for Severe Adverse Events of Chemotherapy with Pemetrexed and Comparison of Adverse Event Occurrence According to Renal Function
Autor: Yasuhiko Sakata, Shinichi Miyamori, Junya Inata, Yasuo Iwamoto, Masashi Kanehara, Kouichi Hiraki, Keisuke Abe
Publikováno v: YAKUGAKU ZASSHI. 133:1209-1213
Various factors, including renal function and the combination of nonsteroidal anti-inflammatory drugs, influence the pharmacokinetics of pemetrexed. In this study, we aimed to determine the risk factors for severe adverse events associated with pemet
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dd0bc5716d33b5f31d5e417a2973b03
https://doi.org/10.1248/yakushi.13-00180
Zobrazit plný text záznamu
7
Efficacy of Olanzapine against Nausea and Vomiting in Cancer Patients Receiving Chemotherapy
Autor: Souichi Kitaguchi, Shinichi Miyamori, Masaaki Noda, Yasuhiko Sakata, Yasuki Tomoda, Chie Hamai, Kouichi Hiraki, Utae Yonezawa, Nobue Uetake, Hidetaka Sumiyoshi, Yasuo Iwamoto
Publikováno v: Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 36:717-722
Nausea and vomiting due to chemotherapy not only reduce quality of life but also cause suspension or extension of therapy,or reductions in the dosages of agents used,and influence therapeutic effects.Their control is therefore extremely important.In
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3401debea3fe517562cf65139aad0873
https://doi.org/10.5649/jjphcs.36.717
Zobrazit plný text záznamu
8
[Assessment of risk factors for adverse events due to pemetrexed in patients with reduced renal function]
Autor: Miho, Kono, Yasuhiko, Sakata, Takafumi, Sugawara, Keisuke, Abe, Shinichi, Miyamori, Shinichiro, Miura, Yusuke, Hata, Masamoto, Funaki, Junya, Inata, Masashi, Kanehara, Kouichi, Hiraki, Yasuo, Iwamoto
Publikováno v: Gan to kagaku ryoho. Cancerchemotherapy. 41(13)
Pemetrexedis a key drug in the first and second -line therapy for non-small-cell lung cancer. It exhibits an increased area under the plasma drug concentration-time curve, and it has a prolonged half -life when administered to patients with reduced r
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a124a5af2ddb9bec069650ef57bc39be
https://pubmed.ncbi.nlm.nih.gov/25596053
Zobrazit plný text záznamu
9
[Adverse events during pemetrexed administration caused by concomitant nonsteroid anti-inflammatory therapy]
Autor: Yasuhiko, Sakata, Yasuo, Iwamoto, Junya, Inata, Shunji, Matsumoto, Shinichi, Miyamori, Kazutoshi, Nakashima, Shinjiro, Sakamoto, Masashi, Kanehara, Souichi, Kitaguchi, Kouichi, Hiraki
Publikováno v: Gan to kagaku ryoho. Cancerchemotherapy. 39(6)
Pemetrexed, a folate metabolic antagonist, is considered to be effective against plural mesotheliomas, non-small cell lung cancer, and especially for non-squamous cell cancer. However, it has been reported to have adverse interactions with nonsteroid
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e35dc88c0140cf4c6b76e9b231b07b4b
https://pubmed.ncbi.nlm.nih.gov/22705687
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje